AUDIT study. Evidence of global undertreatment of dyslipidaemia in patients with type 2 diabetes mellitus

British Journal of Diabetes and Vascular Disease

Volumn 6, Issue 1, 2006, Pages 31-40

  Leiter, Lawrence A ^a   Betteridge, D John ^b   Chacra, Antonio R ^c   Chait, Alan ^d   Ferrannini, Eleuterio ^e   Haffner, Steven M ^f   Kadowaki, Takashi ^g   Tuomilehto, Jaakko ^h   Zimmet, Paul ⁱ   Newman, Connie B ^j   Hey Hadavi, Judith ^j   Walkinshaw, Caroline ^j  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^e INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

^f Mays Cancer Center at UT Health San Antonio   (United States)

^g UNIVERSITY OF TOKYO   (Japan)

^h NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

ⁱ BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^j PFIZER INC   (United States)

more..

Author keywords

Cardiovascular diseases; Guidelines; Hypercholesterolaemia; Lipids; Risk factors; Type 2 diabetes mellitus

Indexed keywords

ANTILIPEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

AFRICA; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DYSLIPIDEMIA; EASTERN EUROPE; HEALTH SURVEY; HUMAN; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MEDICAL AUDIT; MIDDLE EAST; NON INSULIN DEPENDENT DIABETES MELLITUS; NORTH AMERICA; PATIENT COMPLIANCE; PRACTICE GUIDELINE; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SOCIAL STATUS; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 33644759796     PISSN: 14746514     EISSN: None     Source Type: Journal    
DOI: 10.1177/14746514060060010401     Document Type: Article

References (28)

1. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837-53.
2. Kleinman JC, Donahue RP, Harris MI, Finucane FF, Madans JH, Brock DB. Mortality among diabetics in a national sample. Am J Epidemiol 1988; 128:389-401.
3. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-34.
4. Malmberg K, Yusuf S, Gerstein HC et al. Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry. Circulation 2000;102:1014-19.
5. Whiteley L, Padmanabhan S, Hole D, Isles C. Should Diabetes Be Considered a Coronary Heart Disease Risk Equivalent?: Results from 25 years of follow-up in the Renfrew and Paisley Survey. Diabetes Care 2005;28:1588-93.
6. Turner RC, Millns H, Neil HA et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS 23). BMJ 1998;316:823-8.
7. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
8. De Backer G, Ambrosioni E, Borch-Johnsen K et al. European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2003;10:S1-S10.
9. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2005;28(suppl 1):S4-S36.
10. Colhoun HM, Betteridge DJ, Durrington PN et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685-96.
11. Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361:2005-16.
12. Sever PS, Poulter NR, Dahlof B et al. Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA). Diabetes Care 2005;28:1151-7.
13. Pearson TA, Laurora I, Chu H, Kafonek S. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000;160:459-67.
14. Saaddine JB, Engelgau MM, Beckles GL, Gregg EW, Thompson TJ, Narayan KM. A diabetes report card for the United States: quality of care in the 1990s. Ann Intern Med 2002;136:565-74.
15. Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004; 291:335-42.
16. Massing MW, Foley KA, Sueta CA et al. Trends in lipid management among patients with coronary artery disease: has diabetes received the attention it deserves? Diabetes Care 2003;26:991-7.
17. Parris ES, Lawrence DB, Mohn LA, Long LB. Adherence to statin therapy and LDL cholesterol goal attainment by patients with diabetes and dyslipidemia. Diabetes Care 2005;28:595-9.
18. American Diabetes Association. Dyslipidemia management in adults with diabetes. Diabetes Care 2004;27(suppl 1):S68-S71.
19. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348:383-93.
20. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.
21. Sever PS, Dahlof B, Poulter NR et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149-58.
22. Williams B, Poulter NR, Brown MJ et al. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. BMJ 2004;328:634-40.
23. Joint British Societies. JBS2 guidelines on prevention of cardiovascular disease. Heart 2005;91(suppl 1):1-51.
24. Grundy SM, Cleeman JI, Merz CN et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-39.
25. LaRosa JH, LaRosa JC. Enhancing drug compliance in lipid-lowering treatment. Arch Fam Med 2000;9:1169-75.
26. Kiortsis DN, Giral P, Bruckert E, Turpin G. Factors associated with low compliance with lipid-lowering drugs in hyperlipidemic patients. J Clin Pharm Ther 2000;25:445-51.
27. Hobbs FD, Erhardt L. Acceptance of guideline recommendations and perceived implementation of coronary heart disease prevention among primary care physicians in five European countries: the Reassessing European Attitudes about Cardiovascular Treatment (REACT) survey. Fam Pract 2002;19:596-604.
28. Mosca L, Linfante AH, Benjamin EJ et al. National study of physician awareness and adherence to cardiovascular disease prevention guidelines. Circulation 2005;111:499-510.